Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Omrix Biopharmaceuticals Inc.

Division of Johnson & Johnson

Latest From Omrix Biopharmaceuticals Inc.

Medtech Strategic/Start-Up Partnerships: Structuring For Success

According to a panel of strategic investors speaking at a recent IN3 meeting, structured deals that can help manage risk for medtech start-ups seeking funding and strategics looking for growth opportunities are on the rise.

Medical Device Business Strategies

CHMP positives for AbbVie, AstraZeneca, J&J drugs

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended for approval AbbVie's Cholib (fenofibrate/simvastatin), AstraZeneca's Nexium Control (esomeprazole), and Johnson & Johnson's Omrix Biopharmaceuticals' Evarrest (human fibrinogen/human thrombin).

Gastrointestinal Dermatology

Macrocure names Nissim Mashiach CEO

Macrocure, a biotech specialising in cell therapy for hard-to-heal wounds, has appointed Nissim Mashiach president and CEO. Mr Mashiach most recently served as general manager at Ethicon, a Johnson & Johnson company. Prior to that, he was president and COO at Omrix Biopharmaceuticals, a company acquired by J&J for $438 million in 2008.

Johnson & Johnson Enters China’s Device Market Via Guangzhou Bioseal Biotech Acquisition

J&J beefs up in China’s device market with Bioseal Biotech Acquisition

Medical Device China
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Medical Devices
    • Biomaterials
    • Surgical Equipment & Devices
      • Surgical Sealants
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Johnson & Johnson
  • Senior Management
  • Robert Taub, Pres. & CEO
  • Contact Info
  • Omrix Biopharmaceuticals Inc.
    Phone: (212) 209-3901
    708 Third Ave.
    New York, NY 10017